46. Malignant rheumatoid arthritis Clinical trials / Disease details


Clinical trials : 4,325 Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03755258
(ClinicalTrials.gov)
March 16, 201721/11/2018Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid ArthritisA Phase Ib Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GCK in Rheumatoid Arthritis PatientsEarly Rheumatoid ArthritisDrug: GCK 100 mg + Placebo 200 mg;Drug: GCK 200 mg + Placebo 100 mg;Drug: GCK 300 mg;Drug: Placebo 300mgZhejiang Hisun Pharmaceutical Co. Ltd.NULLUnknown status18 Years65 YearsAll128Phase 1China
2ChiCTR-IPR-15006107
2015-03-302015-03-18The clinical trial of tolerance of Ginsenoside compound KTo study the pharmacokinetics and tolerance of Ginsenoside compound K tablet in healthy volunteers after multiple dosing administration rheumatoid arthritisthree groups:Ginsenoside compound K is administrated after single dose or multiple doses;Institute of Clinical Pharmacology, Central South UniversityNULLPending1845Malethree groups:12;I (Phase 1 study)China
3ChiCTR-IPR-15005787
2015-01-152015-01-06The effect of food on the pharmacokinetics of Ginsenoside C-KTo study the effect of food on pharmacokinetics of Ginsenoside C-K tablet in healthy volunteers rheumatoid arthritisTwo groups:Ginsenoside compound K is administrated after taking food versus fasting;Institute of Clinical Pharmacology, Central South UniversityNULLPending1845BothTwo groups:24;I (Phase 1 study)China
4ChiCTR-TRC-14004824
2014-06-232014-06-19Clinical studies on Ginsenoside C-KStudy on tolerability and pharmacokinetics of Ginsenoside C-K tablet in healthy volunteers after a single dose rheumatoid arthritis7 groups:Seven different doses with ginsenoside compound K;Institute of Clinical Pharmacology, Central South UniversityNULLCompleted1845Both7 groups:77;I (Phase 1 study)China